DUBLIN – Sanofi SA is investing €80 million (US$90.8 million) in Biontech AG as part of an extension of an existing alliance to develop synthetic mRNA-based cancer immunotherapies. Mainz, Germany-based Biontech will spend that cash – and a lot more besides – on a shared clinical development program, having exercised an option to co-develop with Paris-based Sanofi the lead candidate therapy from the five-product deal.